急性群発発作市場：薬剤タイプ別、投与経路別、流通チャネル別、地域別

世界の急性群発発作市場は、2024年には31億米ドルと推定され、2024年から2031年までのCAGRは12.6％を示し、2031年には71億2,000万米ドルに達すると予測されます。

図.急性群発発作市場シェア（%）、2024年地域別

急性群発発作（ARS）は、24時間以内に2回以上の誘発性のない発作が発生し、発作と発作の間に意識が回復しないことを特徴とします。急性群発発作は、てんかん患者の疾病負担に大きく寄与しています。世界的にARS患者が増加している要因としては、発作を起こしやすい老年人口の増加、脳卒中、脳損傷、神経感染症に起因するてんかんの有病率の増加が挙げられます。しかし、新世代の抗けいれん薬や病院での緊急治療専用プロトコルなど、ARS治療オプションの進歩が患者を助け、近い将来の市場成長を促進すると期待されています。

市場力学：

世界の急性群発発作市場の成長は、世界のてんかん罹患率の増加によって牽引されています。てんかん患者数は世界で5,000万人と推定されています。さらに、てんかん発作につながる神経障害、脳卒中、脳損傷の影響を受けやすい老年人口の増加が、予測期間中に急性群発発作治療の需要を押し上げています。しかし、低所得地域では救急医療費が高く、アンメット・メディカル・ニーズが市場の成長を妨げる可能性があります。安価なジェネリック抗けいれん薬の開拓は、市場成長の機会を提供します。ARSのタイムリーな特定と治療に関する認識を高めることを目的としたイニシアチブは、死亡率と障害率を低下させることができます。

本調査の主な特徴

• 本レポートでは、世界の急性群発発作市場を詳細に分析し、2023年を基準年とした予測期間（2024-2031年）の市場規模と年間平均成長率（CAGR%）を掲載しています。
• さまざまなセグメントにわたる潜在的な収益成長機会を明らかにし、この市場の魅力的な投資提案マトリクスを解説しています。
• また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域別の展望、主要企業が採用する競争戦略などに関する重要な考察も提供しています。
• 世界の急性群発発作市場における主要企業を、企業ハイライト、製品ポートフォリオ、主要ハイライト、業績、戦略などのパラメータに基づいてプロファイルしています。
• 本レポートからの洞察により、マーケティング担当者や企業の経営陣は、将来の製品上市、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことができます。
• 世界の急性群発発作市場は、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この業界の様々な利害関係者に対応しています。
• 利害関係者は、世界の急性群発発作市場の分析に使用される様々な戦略マトリックスを通じて、意思決定が容易になります。

目次

第1章 調査の目的と前提条件

• 調査目的
• 前提条件
• 略語

第2章 市場の展望

• レポートの説明
  • 市場の定義と範囲
• エグゼクティブサマリー
• Coherent Opportunity Map（COM）

第3章 市場力学、規制、動向分析

• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• 影響分析
• 市場動向
• 主な発展
• 規制シナリオ
• 買収と提携のシナリオ
• 資金調達と投資
• PEST分析
• ポーターの分析

第4章 世界の急性群発発作市場- コロナウイルス（COVID-19）パンデミックの影響

• 全体的な影響
• 政府の取り組み
• COVID-19による市場への影響

第5章 急性群発発作の世界市場、薬剤タイプ別、2019年-2031年

• ベンゾジアゼピン
• 抗てんかん薬
• バルビツール酸
• その他（後期開発品等）

第6章 急性群発発作の世界市場、投与経路別、2019年-2031年

• 経口
• 注射
• その他

第7章 世界の急性群発発作市場、流通チャネル別、2019年-2031年

• 病院薬局
• 小売薬局
• オンライン薬局

第8章 世界の急性群発発作市場、地域別、2019年-2031年

第9章 競合情勢

• 企業プロファイル
  • Neurelis, Inc.
  • Bausch Health Companies Inc.
  • Alexza Pharmaceuticals, Inc.
  • VERITON PHARMA
  • UCB SA
  • Takeda Pharmaceutical Company Limited
  • Pfizer Inc.
  • Sanofi
  • GSK plc
  • Eisai Co., Ltd.
  • H. Lundbeck A/S
  • Cognizance Biomarkers, LLC

第10章 アナリストの提言

• Wheel of Fortune
• アナリストの見解
• Coherent Opportunity Map

第11章 参考文献と調査手法

• 参考文献
• 調査手法

Global acute repetitive seizures market is estimated to be valued at USD 3.10 Bn in 2024 and is expected to reach USD 7.12 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 12.6% from 2024 to 2031.

Figure. Acute Repetitive Seizures Market Share (%), By Region 2024

Acute repetitive seizures (ARS) are characterized by two or more unprovoked seizures occurring within a 24-hour period without restoration of consciousness between the seizures. Acute repetitive seizures contributes significantly to the disease burden among epileptic patients. Factors contributing to increase in ARS cases globally includes growing geriatric population prone to seizures and increasing prevalence of epilepsies arising from strokes, brain injuries, and neuroinfectious. However, advancements in ARS treatment options such as newer generation anticonvulsants and dedicated emergency treatment protocols in hospitals are expected to aid patients and drive the market growth in the near future.

Market Dynamics:

Global acute repetitive seizures market growth is p driven by increasing incidence of epilepsy worldwide. It is estimated that 50 million people suffer from epilepsy globally. Furthermore, rising geriatric population susceptible to neurological disorders, strokes, and brain injuries leading to seizures boosts demand for acute repetitive seizures treatment over the forecast period. However, high costs of emergency care and unmet medical needs in low-income regions can hamper the market growth. Development of inexpensive generic anticonvulsants provides opportunities for the market growth. Initiatives aimed at raising awareness about timely identification and treatment of ARS can reduce mortality and disability rates.

Key Features of the Study:

• This report provides an in-depth analysis of the global acute repetitive seizures market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year.
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global acute repetitive seizures market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this includes Neurelis, Inc., Bausch Health Companies Inc., Alexza Pharmaceuticals, Inc., VERITON PHARMA, UCB S.A., Takeda Pharmaceutical Company Limited, Pfizer Inc., Sanofi, GSK plc, Eisai Co., Ltd., H. Lundbeck A/S, Cognizance Biomarkers, LLC.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global acute repetitive seizures market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global acute repetitive seizures market.

Detailed Segmentation-

• By Drug Type:
  • Benzodiazepines
  • Antiepileptic drugs
  • Barbiturates
  • Others (Late Phase Drugs, etc.)
• By Route of Administration:
  • Oral
  • Injectable
  • Others
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Neurelis, Inc.
  • Bausch Health Companies Inc.
  • Alexza Pharmaceuticals, Inc.
  • VERITON PHARMA
  • UCB S.A.
  • Takeda Pharmaceutical Company Limited
  • Pfizer Inc.
  • Sanofi
  • GSK plc
  • Eisai Co., Ltd.
  • Lundbeck A/S
  • Cognizance Biomarkers, LLC

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Type
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Acquisitions and Partnerships Scenario
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Acute Repetitive Seizures Market - Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Acute Repetitive Seizures Market, By Drug Type, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Benzodiazepines
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Antiepileptic drugs
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Barbiturates
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Others (Late Phase Drugs, etc.)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Acute Repetitive Seizures Market, By Route of Administration, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Injectable
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Acute Repetitive Seizures Market, By Distribution Channel, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Acute Repetitive Seizures Market, By Region, 2019 - 2031, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, For Region, 2020-2031
  • Regional Trends
    • North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • U.S.
    • Canada
    • Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
    • Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Company Profiles
  • Neurelis, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Bausch Health Companies Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Alexza Pharmaceuticals, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • VERITON PHARMA
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • UCB S.A.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Takeda Pharmaceutical Company Limited
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Pfizer Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Sanofi
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • GSK plc
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Eisai Co., Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • H. Lundbeck A/S
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Cognizance Biomarkers, LLC
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact